In a notable exercise of judicial restraint, the Supreme Court of India on Friday, March 13, 2026, refused to entertain a Public Interest Litigation (PIL) seeking to make Nucleic Acid Amplification Testing (NAT) mandatory in all blood banks nationwide. A bench comprising Chief Justice Surya Kant and Justice Joymalya Bagchi observed that the judiciary is not equipped to override experts on matters of medical science, particularly when they involve complex financial and infrastructural considerations across diverse states.
The petitioner, the Sarvesham Mangalam Foundation, had argued that NAT is essential to fulfill the “Right to Safe Blood” under Article 21, citing cases where patients—particularly those with Thalassemia—contracted life-threatening infections through transfusions.
The “Knowledge Gap” vs. Policy
The bench made it clear that while blood safety is a critical fundamental right, the specific method of testing is a policy decision for the executive branch.
- Expertise Argument: The Chief Justice remarked, “Why should we pretend that we know medical science?” asserting that the court should not impose a specific diagnostic technology without specialized knowledge.
- Financial Implications: The court highlighted that every state has different fiscal limitations. Mandatory NAT implementation would require significant investment in equipment and skilled personnel that “economically weaker states” might struggle to afford.
- Foreign Funding Queries: During the hearing, the bench also questioned the counsel about the source of the PIL’s funding, asking, “Do you think PILs are not funded from abroad?”
Comparative: ELISA vs. NAT
The current standard in India under the Drugs and Cosmetics Act is the serological ELISA test. The PIL argued this is insufficient for modern safety standards.
| Feature | ELISA (Current Standard) | NAT (Proposed Mandate) |
| Detection Basis | Detects antibodies/antigens (immune response). | Detects viral genetic material (DNA/RNA). |
| Window Period | 20–60 days (Infection may be missed). | 5–10 days (Narrows the danger gap). |
| Cost per Unit | Significantly cheaper and widely available. | ₹500–₹1,000 higher per unit. |
| Infrastructure | Standard laboratory equipment. | Requires molecular biology labs and specialized staff. |
Status of Blood Safety Tragedies
The PIL was spurred by recent failures in the blood transfusion system that led to devastating outcomes for vulnerable patients:
- Madhya Pradesh (2025): Six Thalassemic children tested HIV-positive after transfusions at Satna District Hospital.
- Jharkhand (2025): Five children infected with HIV at Sadar Hospital, Chaibasa.
- Uttar Pradesh (2023): 14 children contracted Hepatitis and HIV at a state medical college.
[Image: A map showing the “Thalassemia Belt” in India, emphasizing the regions where safe blood transfusion is most critical for survival.]
Key Takeaways
- The Directive: The court disposed of the plea by directing the petitioner to submit a comprehensive representation to the Health Secretaries of all States and Union Territories.
- The “Right to Safe Blood”: While the court did not mandate the test, it acknowledged the importance of the issue, leaving it to domain experts to decide on the most viable testing protocols.
- Regulatory Landscape: The Ministry of Health recently released the Draft Drugs (Amendment) Rules, 2026 (March 11), which seeks to align blood product testing with international standards, suggesting that policy changes are already in motion at the executive level.
Sources
- Business Standard: SC refuses to entertain plea seeking mandatory NAT, March 13, 2026.
- LiveLaw: Supreme Court Refuses To Entertain Plea For Mandatory NAT, March 13, 2026.
- Hindustan Times: Plea over NAT in blood banks: Why should we pretend we know medical science, says SC, March 13, 2026.
Leave a Reply